{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:49:10Z","timestamp":1771062550700,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172785, 81902577, 81974398, 81872107 and 82203110"],"award-info":[{"award-number":["82172785, 81902577, 81974398, 81872107 and 82203110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172785, 81902577, 81974398, 81872107 and 82203110"],"award-info":[{"award-number":["82172785, 81902577, 81974398, 81872107 and 82203110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Foundation for the Postdoctoral Program of Sichuan University","award":["2021SCU12014"],"award-info":[{"award-number":["2021SCU12014"]}]},{"name":"1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University","award":["ZYJC21020"],"award-info":[{"award-number":["ZYJC21020"]}]},{"DOI":"10.13039\/100012542","name":"Science and Technology Support Program of Sichuan Province","doi-asserted-by":"crossref","award":["2021YFS0119"],"award-info":[{"award-number":["2021YFS0119"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00432-023-04639-9","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T22:13:59Z","timestamp":1679868839000},"page":"7247-7258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"149","author":[{"given":"Nanwei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinge","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengnian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangxi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linmao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diming","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuntian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuyi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaowen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"4639_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1530\/ERC-14-0071","volume":"21","author":"SL Burgio","year":"2014","unstructured":"Burgio SL et al (2014) Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer 21:487\u2013493. https:\/\/doi.org\/10.1530\/ERC-14-0071","journal-title":"Endocr Relat Cancer"},{"key":"4639_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/pros.22890","volume":"74","author":"V Conteduca","year":"2014","unstructured":"Conteduca V et al (2014) Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate 74:1691\u20131696. https:\/\/doi.org\/10.1002\/pros.22890","journal-title":"Prostate"},{"key":"4639_CR3","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.molonc.2015.02.010","volume":"9","author":"Q Dang","year":"2015","unstructured":"Dang Q et al (2015) Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells \u2013> androgen receptor (AR) \u2013> miRNA32 signals. Mol Oncol 9:1241\u20131251. https:\/\/doi.org\/10.1016\/j.molonc.2015.02.010","journal-title":"Mol Oncol"},{"key":"4639_CR4","doi-asserted-by":"publisher","first-page":"8126087","DOI":"10.1155\/2018\/8126087","volume":"2018","author":"P Di Giacinto","year":"2018","unstructured":"Di Giacinto P et al (2018) Chromogranin A: from laboratory to clinical aspects of patients with neuroendocrine tumors. Int J Endocrinol 2018:8126087. https:\/\/doi.org\/10.1155\/2018\/8126087","journal-title":"Int J Endocrinol"},{"key":"4639_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/pros.23397","volume":"77","author":"B Dong","year":"2017","unstructured":"Dong B et al (2017) Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer. Prostate 77:1373\u20131380. https:\/\/doi.org\/10.1002\/pros.23397","journal-title":"Prostate"},{"key":"4639_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/bju.13781","volume":"120","author":"L Fan","year":"2017","unstructured":"Fan L et al (2017) Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. BJU Int 120:226\u2013232. https:\/\/doi.org\/10.1111\/bju.13781","journal-title":"BJU Int"},{"key":"4639_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/pros.23762","volume":"79","author":"L Fan","year":"2019","unstructured":"Fan L et al (2019) Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. Prostate 79:567\u2013573. https:\/\/doi.org\/10.1002\/pros.23762","journal-title":"Prostate"},{"key":"4639_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S (2022) Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther 7:198. https:\/\/doi.org\/10.1038\/s41392-022-01042-7","journal-title":"Signal Transduct Target Ther"},{"key":"4639_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bju.13493","volume":"119","author":"MM Heck","year":"2017","unstructured":"Heck MM et al (2017) Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy. BJU Int 119:30\u201337. https:\/\/doi.org\/10.1111\/bju.13493","journal-title":"BJU Int"},{"key":"4639_CR10","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.eururo.2003.11.032","volume":"45","author":"D Hirano","year":"2004","unstructured":"Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N (2004) Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45:586\u2013592. https:\/\/doi.org\/10.1016\/j.eururo.2003.11.032. (discussion 592)","journal-title":"Eur Urol"},{"key":"4639_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.5858\/arpa.2019-0434-RA","volume":"144","author":"J Hu","year":"2020","unstructured":"Hu J, Han B, Huang J (2020) Morphologic spectrum of neuroendocrine tumors of the prostate: an updated review. Arch Pathol Lab Med 144:320\u2013325. https:\/\/doi.org\/10.5858\/arpa.2019-0434-RA","journal-title":"Arch Pathol Lab Med"},{"key":"4639_CR12","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1158\/0008-5472.Can-03-3117","volume":"64","author":"RJ Jin","year":"2004","unstructured":"Jin RJ et al (2004) NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Can Res 64:5489\u20135495. https:\/\/doi.org\/10.1158\/0008-5472.Can-03-3117","journal-title":"Can Res"},{"key":"4639_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15647","author":"A Kannan","year":"2021","unstructured":"Kannan A et al (2021) Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis. BJU Int. https:\/\/doi.org\/10.1111\/bju.15647","journal-title":"BJU Int"},{"key":"4639_CR14","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.lfs.2009.03.021","volume":"84","author":"Y Li","year":"2009","unstructured":"Li Y et al (2009) Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells. Life Sci 84:882\u2013887. https:\/\/doi.org\/10.1016\/j.lfs.2009.03.021","journal-title":"Life Sci"},{"key":"4639_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.4103\/1008-682X.123669","volume":"16","author":"J Lipianskaya","year":"2014","unstructured":"Lipianskaya J et al (2014) Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation. Asian J Androl 16:541\u2013544. https:\/\/doi.org\/10.4103\/1008-682X.123669","journal-title":"Asian J Androl"},{"key":"4639_CR16","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1530\/erc-17-0269","volume":"25","author":"V Marotta","year":"2018","unstructured":"Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A (2018) Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer 25:R11-r29. https:\/\/doi.org\/10.1530\/erc-17-0269","journal-title":"Endocr Relat Cancer"},{"key":"4639_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.dld.2008.05.002","volume":"41","author":"S Massironi","year":"2009","unstructured":"Massironi S et al (2009) Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Digestive Liver Dis: off J Italian Soc Gastroenterol Italian Assoc Study Liver 41:31\u201335. https:\/\/doi.org\/10.1016\/j.dld.2008.05.002","journal-title":"Digestive Liver Dis: off J Italian Soc Gastroenterol Italian Assoc Study Liver"},{"key":"4639_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.clgc.2011.12.004","volume":"10","author":"DV Matei","year":"2012","unstructured":"Matei DV et al (2012) Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt. Clin Genitourin Cancer 10:164\u2013173. https:\/\/doi.org\/10.1016\/j.clgc.2011.12.004","journal-title":"Clin Genitourin Cancer"},{"key":"4639_CR19","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.5301\/ijbm.5000278","volume":"32","author":"G Mikkelsen","year":"2017","unstructured":"Mikkelsen G, \u00c5sberg A, Hultstr\u00f6m ME, Aasar\u00f8d K, Hov GG (2017) Reference limits for chromogranin A, CYFRA 21\u20131, CA 125, CA 19\u20139 and carcinoembryonic antigen in patients with chronic kidney disease. Int J Biol Markers 32:e461\u2013e466. https:\/\/doi.org\/10.5301\/ijbm.5000278","journal-title":"Int J Biol Markers"},{"key":"4639_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1530\/eje.1.01862","volume":"152","author":"M Peracchi","year":"2005","unstructured":"Peracchi M et al (2005) Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 152:443\u2013448. https:\/\/doi.org\/10.1530\/eje.1.01862","journal-title":"Eur J Endocrinol"},{"key":"4639_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030593","author":"L Puca","year":"2019","unstructured":"Puca L, Vlachostergios PJ, Beltran H (2019) Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a030593","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4639_CR22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol: off J Am Soc Clin Oncol 34:1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"key":"4639_CR23","first-page":"23","volume":"18","author":"R Sidhu","year":"2009","unstructured":"Sidhu R, McAlindon ME, Leeds JS, Skilling J, Sanders DS (2009) The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. J Gastrointestinal Liver Dis: JGLD 18:23\u201326","journal-title":"J Gastrointestinal Liver Dis: JGLD"},{"key":"4639_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123792","author":"N Spetsieris","year":"2020","unstructured":"Spetsieris N, Boukovala M, Patsakis G, Alafis I, Efstathiou E (2020) Neuroendocrine and aggressive-variant prostate cancer. Cancers (basel). https:\/\/doi.org\/10.3390\/cancers12123792","journal-title":"Cancers (basel)"},{"issue":"265","key":"4639_CR25","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/j.urolonc.2014.08.007","volume":"33","author":"CI Surcel","year":"2015","unstructured":"Surcel CI et al (2015) Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. Urol Oncol 33(265):e261-267. https:\/\/doi.org\/10.1016\/j.urolonc.2014.08.007","journal-title":"Urol Oncol"},{"key":"4639_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/bju.15086","volume":"127","author":"T Szarvas","year":"2021","unstructured":"Szarvas T et al (2021) Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. BJU Int 127:44\u201355. https:\/\/doi.org\/10.1111\/bju.15086","journal-title":"BJU Int"},{"key":"4639_CR27","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.21873\/anticanres.11931","volume":"37","author":"JH Von","year":"2017","unstructured":"Von JH et al (2017) Prospective evaluation of neuromediator dynamics in castration-resistant prostate cancer patients during docetaxel. Anticancer Res 37:5117\u20135124. https:\/\/doi.org\/10.21873\/anticanres.11931","journal-title":"Anticancer Res"},{"key":"4639_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H (2021) Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep 23:15. https:\/\/doi.org\/10.1007\/s11912-020-01003-9","journal-title":"Curr Oncol Rep"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04639-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04639-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04639-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T17:23:31Z","timestamp":1690478611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04639-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4639"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04639-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"23 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is an observational study. The West China Hospital Ethics Committee has confirmed that no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}